Innate Pharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio7.953.434.5814.243.92
P/B Ratio18.114.074.873.271.75
Price/Tangible Book18.114.105.025.562.49
Enterprise Value Ratios
EV/Revenue5.152.653.1910.072.07
EV/EBITDA10.86
EV/EBIT133.87
Profitability & Returns
Return on Equity (ROE)-1.63%-0.14%-0.72%-0.35%0.00%
Return on Assets (ROA)-0.23%-0.04%-0.04%-0.10%0.00%
Return on Invested Capital (ROIC)-1.23%-1.73%0.05%
Return on Capital Employed (ROCE)-0.66%-0.09%-0.10%-0.26%0.00%
Leverage & Solvency Ratios
Debt/Equity3.510.770.780.410.12
Debt/EBITDA1.33
Liquidity Ratios
Current Ratio2.603.733.381.733.81
Quick Ratio2.503.513.211.673.64
Efficiency Ratios
Asset Turnover0.140.330.250.090.20
Yield & Distribution Ratios
Earnings Yield-0.31%-0.04%-0.22%-0.15%-0.23%
FCF Yield-0.05%-0.16%-0.07%-0.17%-0.19%
Buyback Yield-0.01%-0.01%0.00%-0.01%-0.18%